Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Featured trial
GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

GOG-0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the

  • 679 views
  • 08 Nov, 2020
  • 1 location
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.

  • 0 views
  • 09 Aug, 2021
  • 8 locations
  • 0 views
  • 15 Dec, 2021
  • 2 locations
Submucosal Tumor Removal by Endoscopic Excision Therapy

Smaller submucosal tumors (SMT) in the stomach are usually seen as an incidental finding during a gastroscopy, although current diagnostics usually do not clearly indicate what type of tumor it is. In summary, there is no good evidence for dealing with SMT. In this study, an endoscopic full-thickness resection, primarily …

  • 0 views
  • 01 Jul, 2021
  • 1 location
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, …

cancer
progressive disease
cancer chemotherapy
combination chemotherapy
solid tumour
  • 19 views
  • 11 Apr, 2022
  • 8 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

to accrual 02/06/2018) Vulvar cancer (closed to accrual) MetaPLASTIC carcinoma (of the breast) (closed to accrual) Gastrointestinal stromal tumor (GIST) (closed to accrual

extrahepatic cholangiocarcinoma
pheochromocytoma, malignant
ultrasound examination
oophorectomy
brain metastases
  • 6634 views
  • 10 Aug, 2022
  • 752 locations
PRecision Oncology Evidence Development in Cancer Treatment - Liquid (PREDiCTl)

The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in some countries. This study compares tissue based and liquid based testing to evaluate the detection …

primary cancer
cancer treatment
  • 0 views
  • 09 Aug, 2022
  • 1 location
PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib. In this phase I/II study of PDR001 plus imatinib, it is aimed to evaluate the safety and efficacy of this regimen as 4th line of …

measurable disease
sunitinib
regorafenib
liver metastasis
imatinib
  • 3 views
  • 07 Feb, 2022
  • 1 location
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)

platelet count
neutrophil count
thromboplastin
metastatic gastrointestinal stromal tumor (gist)
imatinib
  • 0 views
  • 25 Feb, 2022
  • 1 location
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)

Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.

platelet count
warfarin
neutrophil count
thromboplastin
lipase
  • 0 views
  • 26 Jan, 2022
  • 15 locations